Avalo Therapeutics, Inc. (AVTX) Financial Statements
Avalo Therapeutics, Inc. (AVTX) reported trailing twelve-month revenue of $59000 (down 86.6% year on year) and net income of -$100.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$68.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVTXAvalo Therapeutics, Inc.Follow AVTX — free
—
Price chart with a free account
- Market cap
- 371.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.8 | 7.0 | 6.8 | 6.7 | 5.4 | 18.1 | 1.9 | 0.4 | 0.1 | — | |
| Gross profit | 27.2 | 3.8 | 7.3 | 6.4 | 3.9 | 14.6 | 0.6 | — | — | — | |
| Research & development | 4.4 | 5.8 | 11.8 | 32.2 | 59.8 | 31.3 | 13.8 | 24.4 | 50.1 | 64.4 | |
| Operating income | 13.9 | -35.4 | -16.1 | -72.8 | -82.1 | -37.4 | -27.4 | -68.5 | -72.9 | -91.4 | |
| Pre-tax income | 13.8 | -35.3 | -15.8 | -66.3 | -84.6 | -41.6 | -31.5 | -35.0 | -78.1 | -100.2 | |
| Income tax | 2.0 | -0.0 | 0.3 | -2.8 | -0.2 | 0.0 | 0.0 | 0.1 | 0.2 | 0.2 | |
| Net income | 11.9 | -40.1 | -16.1 | -63.5 | -84.4 | -41.7 | -31.5 | -35.1 | -78.3 | -100.3 | |
| Diluted EPS ($) | 0.42 | -1.20 | — | — | — | -1063.00 | -113.58 | -20.91 | -5.84 | -2.30 | |
| Diluted shares (mn) | 18.8 | 34.8 | — | — | — | 0.0 | 0.3 | 7.5 | 13.4 | — |
USD millions · SEC XBRL
Avalo Therapeutics, Inc. — questions
- What is Avalo Therapeutics, Inc.'s revenue?
- $59000 over the twelve months to 2026-06-30, down 86.6% year on year, from its 10-Q and 10-K filings.
- What is Avalo Therapeutics, Inc.'s net income?
- -$100.3M over the twelve months to 2026-06-30.
- What is Avalo Therapeutics, Inc.'s free cash flow?
- -$68.3M over the twelve months to 2026-06-30.
- What are Avalo Therapeutics, Inc.'s diluted earnings per share?
- $-2.30 over the twelve months to 2026-06-30.
Every figure on this page comes from Avalo Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.